Spero Therapeutics Inc (SPRO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.13 (+0.89%), Market cap $0.15B, P/E ratio 17.00, 52-week low–high $0.65 ~ $3.04.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater Ch
Financial statements, price targets, institutional (13F) holdings and related news for Spero Therapeutics Inc are updated in real time on BlackAll Trade.
Spero Therapeutics Inc trades at $1.13 (+0.89%). Real-time quotes and charts are available on BlackAll Trade.
Spero Therapeutics Inc has a market cap of about $0.15B. Its P/E ratio is 17.00.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in th